ArticleMicrobiology spectrum2022
Thymol Increases Sensitivity of Clinical Col-R Gram-Negative Bacteria to Colistin.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Thymol and carvacrol againstFrontiers in pharmacology · 2024Pooled it
- Article
- Antibiofilm Activity of Three Essential Oils Against ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Comparison of the antimicrobial, anti-biofilm, and cytotoxic effects of thymol/ampicillin and thymol/cefotaxime against Escherichia coli bacteria.BMC research notes · 2026Article
- Combination of 7-hydroxyflavone and colistin: antibacterial activity and mechanism against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.BMC microbiology · 2026Article
- Research Status and Prospects ofGastroenterology research and practice · 2026Review
- Research progress on the food preservation effects exploiting the antifungal properties of thymol.Food chemistry: X · 2025Review
- Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.Scientific reports · 2025Article
- Single-Atom Cu Anchored on Carbon Nitride as a Bifunctional Glucose Oxidase and Peroxidase Nanozyme for Antibacterial Therapy.ACS nano · 2025Article
- Antimicrobial and Anti-Biofilm Activity of Dichlorophen-Functionalized Gold Nanoparticles Against Carbapenem-ResistantInternational journal of nanomedicine · 2025Article
- Plumbagin enhances antimicrobial and anti-biofilm capacities of chlorhexidine against clinicalMicrobiology spectrum · 2024Article
- The use of combination therapy for the improvement of colistin activity against bacterial biofilm.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Article
- Bavachin Rejuvenates Sensitivity of Colistin against Colistin-Resistant Gram-Negative Bacteria.International journal of molecular sciences · 2024Article
- Polymyxin B adjuvants against polymyxin B- and carbapenem-resistant Gram-negative bacteria.Future microbiology · 2024Article
- A potential strategy against clinical carbapenem-resistant Enterobacteriaceae: antimicrobial activity study of sweetener-decorated gold nanoparticles in vitro and in vivo.Journal of nanobiotechnology · 2023Article
- The Combination of Antibiotic and Non-Antibiotic Compounds Improves Antibiotic Efficacy against Multidrug-Resistant Bacteria.International journal of molecular sciences · 2023Review
- Thymol-Decorated Gold Nanoparticles for Curing Clinical Infections Caused by Bacteria Resistant to Last-Resort Antibiotics.mSphere · 2023Article
- Evaluation of the antibacterial, antibiofilm, and anti-virulence effects of acetic acid and the related mechanisms on colistin-resistant Pseudomonas aeruginosa.BMC microbiology · 2022Article
- Protective Effects of Natural Antioxidants on Inflammatory Bowel Disease: Thymol and Its Pharmacological Properties.Antioxidants (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colistin-resistant (Col-R) bacteria are increasing sharply, which poses a serious threat to public health. Thymol is a phenolic compound used for its wide-spectrum antimicrobial activity, while the combination of nontraditional drugs to restore colistin activity is an attractive strategy to treat infections caused by these pathogens. This study showed that thymol could play a synergistic role with colistin against Gram-negative bacteria (GNB), including nonfermenting bacteria and Enterobacteriaceae. According to antimicrobial resistance profiles, most of the colistin-resistant strains we collected showed multidrug-resistant (MDR) phenotypes. The checkerboard method and time-kill curve confirmed the synergistic effect of thymol combined with colistin against Col-R GNB. The synergistic antibiofilm activity of thymol combined with colistin was assessed via crystal violet staining and scanning electron microscopy (SEM) assays. Results showed that compared with a single drug, the combination partially destroyed bacterial cells and inhibit the formation of bacterial biofilms. Mechanismly, the thymol/colistin combination synergistically potentiated the antibacterial activity by accelerating the damage and permeability of the bacterial outer membrane. Preliminary data indicated that the thymol/colistin combination could decrease the number of bacteria ≥2 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.